Dualitas Therapeutics Appoints Karim Dabbagh as Chief Executive Officer to Advance Novel Bispecific Antibody Pipeline Toward the Clinic

Karim Dabbagh, Ph.D., joins as CEO, bringing leadership experience in advancing immunology and inflammation therapies through clinical trials; Rich Murray, Ph.D., former interim CEO, remains on the Board of Directors Dualitas announces the nomination of DTX-102 as its lead development...